We recently published a list of 10 Small–Cap Stocks Insiders Are Selling Recently. In this article, we are going to take a look at where Travere Therapeutics, Inc. (NASDAQ:TVTX) stands against other ...

Guggenheim analyst Vamil Divan raised the firm’s price target on Travere Therapeutics (TVTX) to $47 from $45 and keeps a Buy rating on the ...

Calvin Sandra, the Senior Vice President and Chief Accounting Officer at Travere Therapeutics, Inc. (NASDAQ:TVTX), executed a ...

Travere Therapeutics (NASDAQ:TVTX – Get Free Report) had its target price hoisted by equities researchers at Canaccord Genuity Group from $22.00 to $45.00 in a research report issued on ...

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life ...

SAN DIEGO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2024 financial results on Thursday, February 20 ...

Scotiabank analyst Greg Harrison raised the firm’s price target on Travere Therapeutics (TVTX) to $32 from $27 and keeps an Outperform rating on the shares. The company recently announced plans to ...

Travere’s stock price climbed by 14% following the announcement it will seek an FDA label expansion for Filspari.